Wall Street Zen Upgrades uniQure (NASDAQ:QURE) to Hold

uniQure (NASDAQ:QURE) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other equities research analysts have also recently commented on the company. Royal Bank Of Canada dropped their target price on uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. HC Wainwright cut their price objective on uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. Guggenheim raised their target price on uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Finally, Benchmark reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $60.82.

uniQure Stock Performance

Shares of QURE opened at $23.39 on Friday. The firm has a market capitalization of $1.46 billion, a PE ratio of -5.33 and a beta of 0.68. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a 50-day moving average price of $30.01 and a 200 day moving average price of $27.30. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. On average, sell-side analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, Director Robert Gut sold 31,434 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the sale, the director owned 40,145 shares in the company, valued at $1,094,352.70. The trade was a 43.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack Kaye sold 38,810 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $620,119.26. This represents a 65.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC raised its position in uniQure by 22.6% during the third quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after buying an additional 819,444 shares during the period. Aberdeen Group plc grew its stake in uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after acquiring an additional 189,029 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of uniQure in the 2nd quarter valued at about $29,217,000. Franklin Resources Inc. lifted its position in shares of uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after purchasing an additional 383,066 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.